# Follow-up
[ ] What is PRNT? May need to check audio and fox everywhere

# Notable
60


# 12-29-24
[ ] consider step to determine if question is compound and should be split
[ ] could do function call to categorize each question


[ ] implement 2 similarity thresholds
    [ ] higher auto threshold - reject questions above automatically
    [ ] lower manual review threshold - can do after the fact and shows all relevant info for fast review
        - questions aligned one on top of the other

<< EXAMPLE OF EXTRACT LOG AFTER FIRST ROUND OF EXTRACTION >>
### extract log
datetime: 2024-12-27 16:40:00 UTC-08:00 America/Los_Angeles
function: primary.llm.create_qa_file_from_transcript_sections
prompt: FCALL_SYSTEM_PROMPT_QA_QONLY_EXPLICIT_1A
tools: tools_qa_sections_1
prep: primary.llm.add_transcript_section_delimiters for non-FDA speakers
model: gpt-4o-2024-11-20
number of characters in transcript: 42,276

#### Section 1 of 16
##### Explicit Questions - before deduplication
None

#### Section 2 of 16
##### Explicit Questions - before deduplication
Q 2-1:  What is the FDA guidance on consolidating a LAMP primer set to enable open-source, low-cost COVID-19 diagnostic assays?
Q 2-2:  Does using the same primers and LAMP mix simplify separate EUAs for different purification methods?

...


# 12-28-24
Tried a full prompt with previous questions repeated 3 times but it's not really better so go back to version -1
data/floodlamp/reg/fda-townhalls/dev-qa-extract/VTH 36_qa-sec_zz-oai-4-prevQ3times.md
        full_prompt = (
            f"{prev_questions_context}\n"
            f"{fcall_prompt}\n\n"
            f"<PREVIOUS QUESTIONS>\n{prev_questions_context}</PREVIOUS QUESTIONS>\n"
            f"<PREVIOUS QA BLOCK>\n{prev_block_context}</PREVIOUS QA BLOCK>\n"
            f"<TRANSCRIPT SECTION>\n{transcript_section}</TRANSCRIPT SECTION>\n"
            f"<FINAL INSTRUCTION> Review again these {prev_questions_context} </FINAL INSTRUCTION>."
        )


Why did it get stuck? Is the previous questions not prominent enough?
### extract log
datetime: 2024-12-28 05:44:02 UTC-08:00 America/Los_Angeles
function: primary.llm.create_qa_file_from_transcript_sections
prompt: You
tools: tools_qa_sections_1
prep: primary.llm.add_transcript_section_delimiters for non-FDA speakers
provider: anthropic
model: claude-3-5-sonnet-20241022
number of characters in transcript: 42,276

#### Processing section 1 of 16
QA Block 1:
CLARIFIED QUESTION: What are the FDA's recent authorizations regarding COVID-19 test pooling, and what is the guidance on using pooling for asymptomatic screening?
QA Block 2:
CLARIFIED QUESTION: What are the FDA's recent COVID-19 test authorizations and current development priorities?
QA Block 3:
CLARIFIED QUESTION: What are the FDA's recent authorizations regarding COVID-19 test pooling, and what is the guidance on using pooling for asymptomatic screening?
QA Block 4:
CLARIFIED QUESTION: What are the FDA's recent COVID-19 test authorizations and current development priorities?
QA Block 5:
CLARIFIED QUESTION: What is the FDA's guidance on using COVID-19 test pooling for asymptomatic screening in low-prevalence settings?
QA Block 6:
CLARIFIED QUESTION: What are the FDA's recent COVID-19 test authorizations and current development priorities?
QA Block 7:
CLARIFIED QUESTION: What is the FDA's guidance on off-label use of COVID-19 tests for asymptomatic screening when pooling is not specifically authorized?
QA Block 8:
CLARIFIED QUESTION: What are the FDA's recent COVID-19 test authorizations and current development priorities?

### full_prompt: 
You are an expert text analyzer trained in identifying questions and answers in transcript sections of dialogue, specifically for FDA Town Hall meetings on COVID-19 diagnostics.

Your Role:
- Determine whether there is important content that should be extracted as an additional question-answer (QA) block, with the provided context of a list of the last several previous questions and the complete previous QA block.
- If additional important content is present, extract and clarify the next question-answer block from the provided transcript chunk.
- If no additional important content is present, respond with "NO NEW QUESTION" for the clarified_question field and leave the other fields blank (empty strings) or zero.
- Extract only new, distinct question-answer content that appears after the text already covered by the previous QA block. Do not duplicate an already-extracted Q&A from the same text segment. However, if there is new or distinct content within a previously introduced speaker response that was never captured, you may extract it now.
- Provide both verbatim and clarified versions of the question and answer to ensure thorough coverage and readability.

Important Note on Use Case:
- Only the clarified_question field will be indexed and used for semantic search. Therefore, the coverage of each new topic or keyword must appear in the question, ensuring users can find it later by searching. If an answer covers multiple distinct topics, you should form multiple questions, even if they overlap in the answer text, so that each topic appears in its own question for better searchability.
- In other words, the question text itself must include key terms, phrases, or concepts from the answer. This way, anyone searching for those terms will retrieve the relevant QA block. Redundant or nearly duplicated questions should be avoided, but it’s acceptable for multiple different questions to reference the same or partially overlapping answer segments if each question addresses a unique aspect that users might search for.

Coverage & Redundancy Guidelines:
- **Focus on distinct, significant content**: Extract only genuinely new information or materially different perspectives on a topic.
- **Avoid splitting related points**: If multiple statements support the same core concept, combine them into a single comprehensive Q&A rather than creating separate blocks.
- **Prioritize unique regulatory guidance**: Focus especially on FDA directives, policy changes, and official clarifications.
- **Consolidate similar topics**: When multiple speakers discuss the same topic, combine their key points into a single thorough Q&A unless they present contradictory or significantly different information.
- **Distinguish truly new content**: Before creating a new QA block, verify that the information isn't effectively covered by previous blocks in the section, even if phrased differently.

Redundancy Prevention:
- Before extracting a new QA block, carefully review the previous questions and answers in this section.
- Do not create a new block if the core information is already captured, even if expressed differently.
- When in doubt about whether content is sufficiently distinct, prefer consolidating into existing QA blocks over creating new ones.
- Multiple perspectives on the same topic should be combined unless they present materially different information or contradictory guidance.

Speaker Guidelines:
- Speakers are identified by lines ending with a colon, timestamp, or by a direct statement of their role (e.g., "Dr. Smith (FDA):").
- Authority Speakers are indicated by 'FDA' in their role description.
- Non-Authority Speaker statements must be included in the clarified_answer field if they contain important details or are directly addressed by the FDA. If uncertain, set review_flag = True.

Content Guidelines:
- Focus on technical, procedural, or legal aspects of COVID-19 diagnostics (test development, validation, labeling, etc.).
- Exclude trivial or orchestration details like meeting start-up or speaker order.
- If important FDA information is present but no explicit question is asked, generate an “implied” question.
- Whenever uncertain, set review_flag to True.
- Combine related points into comprehensive QA blocks rather than creating multiple overlapping blocks.
- Focus on extracting genuinely new information rather than different phrasings of the same guidance.

Verbatim vs. Clarified Output:
- Provide both verbatim_question and verbatim_answer, exactly as they appear in the transcript (minus speaker labels and newlines).
- Provide clarified_question and clarified_answer for conciseness, improved clarity, and readability.

Option to Return “NO NEW QUESTION”:
- If no new question is found, set "clarified_question" to the exact string "NO NEW QUESTION" and leave the other fields blank (empty strings) or zero. 
- Set "review_flag" to True if there is significant uncertainty in whether new QA content is present, or False if there is clearly no remaining new content given the provided context in the form of the previous list of several questions and previous entire QA block.
- If the previously extracted QA block is empty or nonexistent, extract the earliest important content as the new Q&A, since there are no previous questions to consider.
- You **must extract at least one question-answer block** from each transcript section.

Remember, the user’s application will index only the questions for semantic search, so your clarified_question fields must capture all key points that a user might search for in the future. Avoid discarding or merging clearly separate topics into one question.
Your output must strictly follow the schema. All fields are required, so if there is no new QA, fill them with the agreed-upon placeholders or zeros.

The transcript will be processed in a progressive manner with the response being one in a sequence.


#### Previous questions (from most recent to oldest):
1. What are the FDA's recent authorizations and current priorities for COVID-19 testing, particularly regarding pooling strategies and asymptomatic screening?

#### Previous Question-Answer Block:
CLARIFIED QUESTION: What are the FDA's recent authorizations and current priorities for COVID-19 testing, particularly regarding pooling strategies and asymptomatic screening?
CLARIFIED ANSWER: The FDA has authorized several new pooling strategies particularly useful for identifying asymptomatic positive patients in low-prevalence settings like universities and workplaces. Pooling is efficient when regular screening programs lead to declining positives. Tests can be used off-label for asymptomatic screening if there are no specific limitations to symptomatic patients only. Recent authorizations include new home collection kits (including the first for a SARS-CoV-2/flu panel test), rapid antigen tests, and serology tests. Current FDA priorities for review and development are: point-of-care tests, home collection kits, home testing opportunities, panels, and extremely high-throughput systems for large volume testing.
VERBATIM QUESTION: IMPLIED QUESTION
VERBATIM ANSWER: Since I last mentioned that we had organized a further surge of resources into the COVID applications, we continue to see success with that surge and see an increasing pace of decisions. So I did want to highlight this week that since last week there have been several additions to our authorization including more pooling authorizations that are especially useful we believe in trying to identify asymptomatic positive patients. When the prevalence of disease is low in a population such as a routinely screened population which is congregant settings or universities and workplaces, colleges, other educational institutions, we expect that once a regular screening program is initiated that you will hopefully rapidly see a decline in positives making pooling a very efficient way, efficient use of resources. Please note all the caveats in our authorizations about the use of pooling. And of course if the pooling scheme has not yet been authorized for an asymptomatic screening we do clearly state on the FDA Web site and we're supported by both the CDC and the CMS that you can use the tests that off label as long as there is no specific limitation about the use, very specific use limitations to very rare perhaps authorizations about the limitations to only symptomatic patients. We also saw more home collection kits authorized and of note the first home collection for a panel test that involves both SARS-CoV-2 and flu detection. And of course we signal with that authorization our continued desire to see panel testing in all forms that are supported by data. We authorized another rapid antigen test. We also authorized more serology tests. And so it has been a busy - another busy week. We - and want to remind everyone of our current highest priorities. This is - this - the priorities in two ways, one for review but also in seeking development of these tests from the development community. so that obviously they really haven't changed recently and so they are again point of care tests, home collection kits from home testing opportunities, panels and extremely high throughput systems that allow the most efficient testing of large volumes of samples.
SPEAKER QUESTION: IMPLIED
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: COVID-19 test pooling strategies, asymptomatic screening, FDA testing priorities
REVIEW FLAG: False


#### Please identify the next question-answer block in this transcript section:

Coordinator (FDA):
Welcome and thank you for standing by. At this time all participants are on listen-only mode until our question-and-answer session. At that time if you would like to ask a question please press Star then 1. Today’s conference is being recorded. If you have any objections you may disconnect at this time. And now I’d like to turn the meeting over to Ms. Irene Aihie. You may begin.

Irene Aihie (FDA Moderator):
Thank you hello. I’m Irene Aihie of CDRH’s Office of Communications and Education. Welcome to the FDA’s 36th in a series of virtual town hall meetings to help answer technical questions about the development and validation of tests for SARS-CoV-2 during the public health emergency. Today Timothy Stenzel, Director of the Office of In Vitro Diagnostics and Radiological Health in the Office of Product Evaluation and Quality and Toby Lowe, Associate Director of the Office of In Vitro Diagnostics and Radiological Health both from CDRH will provide a brief update. Following opening remarks we will open the line for your questions related to today’s discussion. Please remember that we are not able to respond to questions about specific submissions that might be under review. Now I give you Timothy.

Tim Stenzel (FDA IVD Director):
Welcome everyone and we're so glad you could join us again today. And as always our desire is to do our best from the FDA’s perspective to provide clear recommendations and information that you can use to further development of from COVID-19 tests and to continue our mission during this pandemic to speed access to as much accurate testing as possible. Since I last mentioned that we had organized a further surge of resources into the COVID applications, we continue to see success with that surge and see an increasing pace of decisions. So I did want to highlight this week that since last week there have been several additions to our authorization including more pooling authorizations that are especially useful we believe in trying to identify asymptomatic positive patients. When the prevalence of disease is low in a population such as a routinely screened population which is congregant settings or universities and workplaces, colleges, other educational institutions, we expect that once a regular screening program is initiated that you will hopefully rapidly see a decline in positives making pooling a very efficient way, efficient use of resources. Please note all the caveats in our authorizations about the use of pooling. And of course if the pooling scheme has not yet been authorized for an asymptomatic screening we do clearly state on the FDA Web site and we're supported by both the CDC and the CMS that you can use the tests that off label as long as there is no specific limitation about the use, very specific use limitations to very rare perhaps authorizations about the limitations to only symptomatic patients. We also saw more home collection kits authorized and of note the first home collection for a panel test that involves both SARS-CoV-2 and flu detection. And of course we signal with that authorization our continued desire to see panel testing in all forms that are supported by data. We authorized another rapid antigen test. We also authorized more serology tests. And so it has been a busy - another busy week. We - and want to remind everyone of our current highest priorities. This is - this - the priorities in two ways, one for review but also in seeking development of these tests from the development community. so that obviously they really haven’t changed recently and so they are again __point of care tests, home collection kits from home testing opportunities, panels and extremely high throughput systems that allow the most efficient testing of large volumes of samples.__ And so that concludes my introductory remarks today and I look forward to our dialogue. And we can open it up for questions. Thank you.

Coordinator (FDA):
Thank you. We will now begin our question and answer session. If you’d like to ask a question over the phone please press Star then 1 and record your name clearly when prompted. If you need to withdraw your question you may do so by pressing Star then 2. Our first question comes from Randy True. Your line is now open.

#### Processing section 2 of 16
full_prompt: 
You are an expert text analyzer trained in identifying questions and answers in transcript sections of dialogue, specifically for FDA Town Hall meetings on COVID-19 diagnostics.

Your Role:
- Determine whether there is important content that should be extracted as an additional question-answer (QA) block, with the provided context of a list of the last several previous questions and the complete previous QA block.
- If additional important content is present, extract and clarify the next question-answer block from the provided transcript chunk.
- If no additional important content is present, respond with "NO NEW QUESTION" for the clarified_question field and leave the other fields blank (empty strings) or zero.
- Extract only new, distinct question-answer content that appears after the text already covered by the previous QA block. Do not duplicate an already-extracted Q&A from the same text segment. However, if there is new or distinct content within a previously introduced speaker response that was never captured, you may extract it now.
- Provide both verbatim and clarified versions of the question and answer to ensure thorough coverage and readability.

Important Note on Use Case:
- Only the clarified_question field will be indexed and used for semantic search. Therefore, the coverage of each new topic or keyword must appear in the question, ensuring users can find it later by searching. If an answer covers multiple distinct topics, you should form multiple questions, even if they overlap in the answer text, so that each topic appears in its own question for better searchability.
- In other words, the question text itself must include key terms, phrases, or concepts from the answer. This way, anyone searching for those terms will retrieve the relevant QA block. Redundant or nearly duplicated questions should be avoided, but it’s acceptable for multiple different questions to reference the same or partially overlapping answer segments if each question addresses a unique aspect that users might search for.

Coverage & Redundancy Guidelines:
- **Focus on distinct, significant content**: Extract only genuinely new information or materially different perspectives on a topic.
- **Avoid splitting related points**: If multiple statements support the same core concept, combine them into a single comprehensive Q&A rather than creating separate blocks.
- **Prioritize unique regulatory guidance**: Focus especially on FDA directives, policy changes, and official clarifications.
- **Consolidate similar topics**: When multiple speakers discuss the same topic, combine their key points into a single thorough Q&A unless they present contradictory or significantly different information.
- **Distinguish truly new content**: Before creating a new QA block, verify that the information isn't effectively covered by previous blocks in the section, even if phrased differently.

Redundancy Prevention:
- Before extracting a new QA block, carefully review the previous questions and answers in this section.
- Do not create a new block if the core information is already captured, even if expressed differently.
- When in doubt about whether content is sufficiently distinct, prefer consolidating into existing QA blocks over creating new ones.
- Multiple perspectives on the same topic should be combined unless they present materially different information or contradictory guidance.

Speaker Guidelines:
- Speakers are identified by lines ending with a colon, timestamp, or by a direct statement of their role (e.g., "Dr. Smith (FDA):").
- Authority Speakers are indicated by 'FDA' in their role description.
- Non-Authority Speaker statements must be included in the clarified_answer field if they contain important details or are directly addressed by the FDA. If uncertain, set review_flag = True.

Content Guidelines:
- Focus on technical, procedural, or legal aspects of COVID-19 diagnostics (test development, validation, labeling, etc.).
- Exclude trivial or orchestration details like meeting start-up or speaker order.
- If important FDA information is present but no explicit question is asked, generate an “implied” question.
- Whenever uncertain, set review_flag to True.
- Combine related points into comprehensive QA blocks rather than creating multiple overlapping blocks.
- Focus on extracting genuinely new information rather than different phrasings of the same guidance.

Verbatim vs. Clarified Output:
- Provide both verbatim_question and verbatim_answer, exactly as they appear in the transcript (minus speaker labels and newlines).
- Provide clarified_question and clarified_answer for conciseness, improved clarity, and readability.

Option to Return “NO NEW QUESTION”:
- If no new question is found, set "clarified_question" to the exact string "NO NEW QUESTION" and leave the other fields blank (empty strings) or zero. 
- Set "review_flag" to True if there is significant uncertainty in whether new QA content is present, or False if there is clearly no remaining new content given the provided context in the form of the previous list of several questions and previous entire QA block.
- If the previously extracted QA block is empty or nonexistent, extract the earliest important content as the new Q&A, since there are no previous questions to consider.
- You **must extract at least one question-answer block** from each transcript section.

Remember, the user’s application will index only the questions for semantic search, so your clarified_question fields must capture all key points that a user might search for in the future. Avoid discarding or merging clearly separate topics into one question.
Your output must strictly follow the schema. All fields are required, so if there is no new QA, fill them with the agreed-upon placeholders or zeros.

The transcript will be processed in a progressive manner with the response being one in a sequence.


Previous questions (from most recent to oldest):

Please identify the first question-answer block in this transcript section. Every section must have at least one QA block extracted:

Randy True (FloodLAMP PBC):
Hi there Dr. Stenzel. Thank you for doing these town halls. They are very useful. I have a question about establishing a primer set for LAMP. They - I’ve - I’m with a public benefit corporation called FloodLAMP and we are developing a colorimetric LAMP-based assay that has a ultra-cheap front end and then goes into the colorimetric LAMP. And we're coordinating with other test developers who also want to open source our test to provide very low cost scalable options for essentially exactly the scenario that you described above in terms of the screening of - repeated screening of asymptomatic population. So to pursue these together it's going to be very efficient to consolidate on primer set. And for - if we establish a primer set and give a general letter of reference that the CDC did for their primary sets for PCR then it’s my understanding we wouldn’t - each of us individually wouldn't have to repeat certain aspects of the validation. And I just want to understand that dynamic a bit more in terms of the inclusivity in silico analysis and the in silico cross-reactivity and the wet cross-reactivity. Can you sort of speak to that and give us some sort of guidance as we coordinate on this?

Tim Stenzel (FDA IVD Director):
Yes that’s - we’ve seen that as a pathway that could be very successful. Of course the Yale saliva direct was the first to get authorization and we see a lot of interest in this sort of open source. As far as, you know, the data related to test performance yes that can be leveraged in a different - you know, in multiple ways. The two main ways are that if you seek your own authorization for the test you can give a right of reference for anyone else who wants to copy your test. That wouldn’t eliminate the requirement for them to if they're a kit developer say for them to come in to get their own authorization. And it wouldn’t extend the umbrella of an EUA authorization to any lab that might copy that method. So looking at the saliva direct model they have in their original submission and any amendments -- and I have to check what amendments they have to date -- they have an instruction for use that is the sole basis so to speak of the kit. And they point to off-the-shelf product that users can purchase. In the case of primers and probes for their tests - Toby you can correct me but I think it’s the CDC’s. And they can get that from vendors that produce primary probes under that CDC authorization. So those are very specific catalog numbers and those are primers and probes that we previously authorized. So again there’s these two different pathways. I want to lay them out very clearly. You can get your own individual authorization for a kit. You can then give anybody, any other developer the right of reference to that and they can copy it and they can pretty much link up and use the data in your submission. There are some elements that if they were to be changed that we'd want to see. But if they are using the same suppliers for everything - and the same catalog numbers for everything that you’re using then that makes it very easy. Or the other way is to have this method authorized as we did for saliva direct and then you - we would envision giving you or any other sponsors the same sort of flexibility that Yale is actually the one that designates which lab can use their method and are therefore covered by their EUA. And they have commitments to the FDA on what is required in making that determination of designation. And my understanding is they’ve designated quite a few labs already. And I would refer you to them if anybody wants to know those numbers but it appears to be a very highly successful program. So hopefully I've addressed the questions and...

Randy True (FloodLAMP PBC):
Yes, they've been our inspiration for this modality and effort. And I guess just one quick follow-up question. So if we get authorization for a test with a certain license or activation buffer and a certain purification like we're pursuing an ultra-cheap class mill purification and but we're working with another test developer who is seeking authorization for a mag B based purification it would be highly amenable to automation. And so if we consolidated on the same primer set and LAMP master mix then would they need to - they wouldn’t - it's my understanding they would need to repeat the upfront parts, but with respect to the interfering substances would they need to repeat that? And then if we gave them a general right of reference and they would end up getting their own EUA that they could control the designations on as well. And then we would have our - and we would have our own independent EUA that we control the designations on even though we granted a right of reference. Is that how it would work?

Tim Stenzel (FDA IVD Director):
At a high level you’re close. But the devil's sometimes in the detail. There are certain alterations to a test that we may require additional validation. So if they’re adding something new that you didn’t do say then we would want to evaluate the data around that change. And then you absolutely developers can give each other right of references as they so wish. They can specify what right they have or among their - from their entire EUA. They can have limitation or they can open them up entirely. But you can cross - basically cross reference each other’s assays to the extent that you want. And there would absolutely be synergy. And if the components are all the same that they use for the core test then there would absolutely be synergy on reducing any sort of duplication that wouldn’t - that isn’t, you know, recommended because the tests are basically the same in those functions. Okay? So I look forward to hearing more about your development. Thank you so much.

Randy True (FloodLAMP PBC):
Yes thank you very much.

Coordinator (FDA):
Thank you. Our next question comes from Shannon Clark. You're line is now open.
QA Block 2:
CLARIFIED QUESTION: What are the FDA's requirements and pathways for sharing primer set validation data among multiple developers of LAMP-based COVID-19 tests, particularly regarding inclusivity analysis and cross-reactivity testing?


# 12-27-24 Sections
[ ] update create function to add line references for QA sections

o1-pro
[14, 17, 31, 40, 51, 66, 75, 99, 120, 147, 156, 165, 174, 183, 189, 204, 213, 228, 231]
expected output:
[24, 42, 51, 60, 75, 93, 105, 129, 138, 150, 189, 201, 210, 219, 234, 243, 249, 258, 297]

The chunk in history shouldn't be getting reset, it should just accumulate up to the amount. I'd like to know QA found a position should go to the end, not the beginning. And then I need to ask it what's going on after it finds no new QA found at position zero. So after five, what is that extra text that's getting printed there? Something weird is going on.


QA Block (\d+):\nCLARIFIED QUESTION:
## QA Block $1: CLARIFIED QUESTION:

# 12-25-24 Merry Christmas!
[x] clean up llm.py
    - decide if pull out prompts and tools from llm.py
[ ] update code to be able to return NONE when no new questions are found
    - also return next question? ask chatgpt and give it current code
[ ] integrate stuck and question history with old prompt/tools2 with clarified qa
[ ] run on VTH36 again
[ ] compare to prompt2 115q version of VTH36


[ ] run on another VTH
[ ] review and clean up that one
    - how to deal with stuck reporting in terminal output

# 12-24-24 
[NO] create desired version of 1stq

# 12-23-24 0544 just did commit
## prompt5 on 1stq
OPENAI_MODEL = gpt-4o-2024-11-20
Total tokens in the file: 1,984  x 4 for characters: 7,936
Number of segments in the file: 9
Maximum tokens in any segment: 736  x 4 for characters: 2,944
Number of characters in transcript: 17,398

chunk transcript positions: 0 to 3,966 of total: 17,398 | Percent done: 0%
DEBUG: Current chunk_end_history: [3966]
qa response transcript position: 938 to 1,814
QA Block 1:
### QUESTION: What recent updates has the FDA provided on COVID-19 test authorizations and priorities?

Block processed successfully.
chunk transcript positions: 938 to 3,966 of total: 17,398 | Percent done: 5%
DEBUG: Current chunk_end_history: [3966, 3966]
qa response transcript position: 2,345 to 2,841
QA Block 2:
### QUESTION: What are the FDA's current highest priorities in COVID-19 test development and review?

Block processed successfully.
chunk transcript positions: 2,345 to 5,546 of total: 17,398 | Percent done: 13%
DEBUG: Current chunk_end_history: [3966, 3966, 5546]
qa response transcript position: 3,327 to 4,126
QA Block 3:
### QUESTION: What guidance does the FDA provide regarding establishing a primer set for LAMP assays to simplify validation for multiple developers?

Block processed successfully.
chunk transcript positions: 3,327 to 8,075 of total: 17,398 | Percent done: 19%
DEBUG: Current chunk_end_history: [3966, 3966, 5546, 8075]
qa response transcript position: 3,910 to 5,729
QA Block 4:
_QUESTION: What steps should developers take to consolidate and use a primer set for LAMP assays to streamline test validation and authorization?_

Block processed successfully.
chunk transcript positions: 3,910 to 8,075 of total: 17,398 | Percent done: 22%
DEBUG: Current chunk_end_history: [3966, 5546, 8075, 8075]
qa response transcript position: 4,213 to 5,767
QA Block 5:
_QUESTION: What pathways are available for developers establishing a primer set for LAMP to streamline test validation and authorization?_

Block processed successfully.
chunk transcript positions: 4,213 to 8,075 of total: 17,398 | Percent done: 24%
DEBUG: Current chunk_end_history: [5546, 8075, 8075, 8075]
qa response transcript position: 4,485 to 6,222
QA Block 6:
### _QUESTION: What processes can developers follow to consolidate a primer set for LAMP assays and manage inclusivity and cross-reactivity analyses?_

Block processed successfully.
chunk transcript positions: 4,485 to 8,075 of total: 17,398 | Percent done: 26%
DEBUG: Current chunk_end_history: [8075, 8075, 8075, 8075]
__Detected stuck processing - chunks repeatedly ending at position 8,075__
Forcing skip to next chunk starting at: 8,075
chunk transcript positions: 8,075 to 11,452 of total: 17,398 | Percent done: 46%
DEBUG: Current chunk_end_history: [11452]
qa response transcript position: 8,809 to 9,480
QA Block 7:
### QUESTION: Can point-of-care facilities use venous draw whole blood for antibody test kits authorized for fingerstick use, and are there limitations for plasma and serum?

Block processed successfully.
chunk transcript positions: 8,809 to 12,103 of total: 17,398 | Percent done: 51%
DEBUG: Current chunk_end_history: [11452, 12103]
qa response transcript position: 9,818 to 10,191
QA Block 8:
QUESTION: What are the recommendations for low CT values and fresh samples in retrospective studies for rapid antigen tests when using dry swabs that have been frozen instead of samples in VTM?

Block processed successfully.
chunk transcript positions: 9,818 to 13,007 of total: 17,398 | Percent done: 56%
DEBUG: Current chunk_end_history: [11452, 12103, 13007]
qa response transcript position: 10,027 to 10,617
QA Block 9:
QUESTION: What is FDA's position on using venous draw whole blood in point-of-care antibody tests authorized for fingerstick specimens only?

Block processed successfully.
chunk transcript positions: 10,027 to 13,007 of total: 17,398 | Percent done: 58%
DEBUG: Current chunk_end_history: [11452, 12103, 13007, 13007]
qa response transcript position: 11,214 to 11,609
QA Block 10:
QUESTION: What evidence has FDA observed about freeze-thaw processes in retrospective studies for rapid antigen tests?

Block processed successfully.
chunk transcript positions: 11,214 to 14,747 of total: 17,398 | Percent done: 64%
DEBUG: Current chunk_end_history: [12103, 13007, 13007, 14747]
qa response transcript position: 12,424 to 12,997
QA Block 11:
QUESTION: What are FDA's recommendations for validation and authorization of over-the-counter COVID-19 tests?

Block processed successfully.
chunk transcript positions: 12,424 to 16,052 of total: 17,398 | Percent done: 71%
DEBUG: Current chunk_end_history: [13007, 13007, 14747, 16052]
qa response transcript position: 13,566 to 14,153
QA Block 12:
_QUESTION: What are FDA's requirements for software validation in relation to artificial intelligence used in COVID-19 diagnostics and the handling of end-user instrument calibration?_

Block processed successfully.
chunk transcript positions: 13,566 to 17,394 of total: 17,398 | Percent done: 78%
DEBUG: Current chunk_end_history: [13007, 14747, 16052, 17394]
qa response transcript position: 14,719 to 15,354
QA Block 13:
_QUESTION: What is FDA’s general guidance on software validation requirements for EUAs involving artificial intelligence in COVID-19 assays?_

Block processed successfully.
chunk transcript positions: 14,719 to 17,398 of total: 17,398 | Percent done: 85%
DEBUG: Current chunk_end_history: [14747, 16052, 17394, 17398]
qa response transcript position: 14,805 to 16,045
QA Block 14:
_QUESTION: What are FDA's expectations for software validation documentation when seeking an EUA for COVID-19 diagnostics involving artificial intelligence?_

Block processed successfully.
chunk transcript positions: 14,805 to 17,398 of total: 17,398 | Percent done: 85%
DEBUG: Current chunk_end_history: [16052, 17394, 17398, 17398]
qa response transcript position: 14,805 to 16,134
QA Block 15:
_QUESTION: What level of software validation does the FDA require for an EUA submission involving artificial intelligence used in COVID-19 diagnostics?_

Block processed successfully.
chunk transcript positions: 14,805 to 17,398 of total: 17,398 | Percent done: 85%
DEBUG: Current chunk_end_history: [17394, 17398, 17398, 17398]
qa response transcript position: 15,895 to 16,330
QA Block 16:
_QUESTION: What is the FDA's general approach to software documentation requirements for EUAs involving COVID-19 diagnostics?_

Block processed successfully.
chunk transcript positions: 15,895 to 17,398 of total: 17,398 | Percent done: 91%
DEBUG: Current chunk_end_history: [17398, 17398, 17398, 17398]
__Detected stuck processing - chunks repeatedly ending at position 17,398__
Forcing skip to next chunk starting at: 17,398
Reached end of transcript - stopping processing
QA extraction completed due to end of transcript.


